Replies to post #52509 on Biotech Values

[palindromy]

Allergan would have put in the same effort to sell Sanctura regardless of whether royalty was 12.5 or 15. If IDEV really believed Allergan would market Sanctura a lot better, they would not have agreed to the new deal. I fail to see what exactly IDEV is getting for this, even the upfront payment is down the line. Seems like neither IDEV or Allergan really believe in Sanctura.

[rfj1862]

In case nobody's watching, IDEV is very close to 52-week highs post-Allergan deal.